Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 3/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | LATS1 | O95835 | 3/20 | 0.31 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517203 | 0.82 | KDM4C (0.52) | ROCK1KDM4CKDM4ECDC7LATS1 | |
| SCHEMBL16103116 | 0.79 | IDO1 (0.40) | KDM4CIDO1GBA1CYP19A1 | |
| SCHEMBL16101098 | 0.77 | IDO1 (0.42) | KDM4CIDO1GBA1 | |
| SCHEMBL16128821 | 0.77 | CYP19A1 (0.43) | KDM4CGBA1CYP19A1 | |
| SCHEMBL19272656 | 0.74 | CDC7 (0.39) | KDM4CIDO1KDM4EMAPKAPK2CDC7 | |
| SCHEMBL17503825 | 0.73 | KDM4C (0.51) | KDM4CKDM4EMAPKAPK2 | |
| SCHEMBL16095498 | 0.72 | HASPIN (0.39) | KDM4CIDO1KDM4EMAPKAPK2CDC7 | |
| SCHEMBL16128722 | 0.72 | KDM4C (0.44) | KDM4CGBA1CYP19A1 | |
| SCHEMBL16097524 | 0.72 | LRRK2 (0.33) | KDM4C | |
| SCHEMBL17503840 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | claimed |
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2970211-B1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2970211-B1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| EP-2970211-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151106-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151106-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | ROCK1 682/4885KDM4C 9/4885IDO1 262/4885 |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | ROCK1 682/4885KDM4C 9/4885IDO1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.